Dana Farber Cancer Institute, Boston, MA, USA.
Cancer J. 2013 May-Jun;19(3):263-71. doi: 10.1097/PPO.0b013e318297216a.
Lung cancer accounts for the majority of cancer-related deaths worldwide. We sought out to summarize the current state of molecular predictors for response and toxicity in locally advanced lung cancer. Several changes have been introduced in recent years in the standard-of-care treatment of advanced non-small cell lung cancer based on the identification of specific molecular alterations that determine response probability to certain therapies. Eligibility for these treatments is assessed by a biomarker test, evaluating if the molecular alteration is present or not in a patient's tumor. In particular, tissue testing for epidermal growth factor receptor and anaplastic lymphoma kinase alterations is currently recommended for certain patients with advanced non-small cell lung cancer, whereas excision repair cross-complementation group 1 and ribonucleotide reductase 1 as markers for outcome after platinum and gemcitabine therapy are promising but are currently not recommended outside a clinical trial. However, their application to the therapy of locally advanced disease is still mostly investigational. Moreover, additional candidate markers for response and toxicity for locally advanced lung cancer are under further investigation.
肺癌是全球癌症相关死亡的主要原因。我们旨在总结目前局部晚期肺癌反应和毒性的分子预测因子的现状。近年来，根据确定对某些治疗方法反应概率的特定分子改变，在晚期非小细胞肺癌的标准治疗中引入了一些改变。这些治疗的资格通过生物标志物测试进行评估，评估患者肿瘤中是否存在分子改变。特别地，目前推荐对某些晚期非小细胞肺癌患者进行表皮生长因子受体和间变性淋巴瘤激酶改变的组织检测，而切除修复交叉互补组 1 和核糖核苷酸还原酶 1 作为铂类和吉西他滨治疗后结局的标志物具有很大的应用前景，但目前在临床试验之外不推荐使用。然而，它们在局部晚期疾病治疗中的应用仍在很大程度上处于研究阶段。此外，局部晚期肺癌反应和毒性的其他候选标志物也在进一步研究中。
